Notice for International Patients & Caregivers

English summary does not mean the trial enrolls international patients. Multiple myeloma interventional clinical trials in China typically require valid Chinese resident identity/national healthcare insurance and strict adherence to China's Human Genetic Resources Administration regulations.

Provincial Landscape
Snapshot: 2026-10-21

Chongqing Multiple Myeloma Active Trials & Centers

As of 2026-10-21, there are 17 active clinical trials for multiple myeloma hosted across 7 tertiary medical centers in Chongqing (including Chongqing University Cancer Hospital (Chongqing Cancer Hospital), The First Affiliated Hospital of Chongqing Medical University, The Second Affiliated Hospital of Army Medical University, etc.).

Active Trials
17
Hospitals
7
Therapies
CAR-T Cell Therapy / Bispecific & Multispecific Antibodies / Monoclonal Antibodies / Oral Small-Molecule Agents

Participating Medical Centers (7)

Chongqing University Cancer Hospital (Chongqing Cancer Hospital)The First Affiliated Hospital of Chongqing Medical UniversityThe Second Affiliated Hospital of Army Medical UniversityChongqing University Cancer HospitalThe Second Affiliated Hospital of Chongqing Medical UniversityChongqing University Three Gorges HospitalXinqiao Hospital, Army Medical University

Active Studies in Chongqing (17)

Population synthesized by CMDN

Showing 0 published English records of 17 registry trials.

All 17 local registry studies currently have Chinese-only filings. Verified English summaries will be published upon regulatory audit.